Status: Finalised First registered on: 03/11/2015
Last updated on: 23/10/2018
1. Study identification
EU PAS Register NumberEUPAS11512
Official titleThe role of adherence to inhaled corticosteroids in the relationship between blood eosinophilia and asthma control
Study title acronym
Study typeObservational study
Brief description of the studyPatients with asthma and >0.4x109 blood eosinophils/L are characterized by increased severe exacerbation rates, reduced odds of achieving asthma control and being at higher steps of the GINA guidelines (step 3-4), compared to patients with asthma and lower eosinophil counts (<0.4x109/L). Alternative therapies that target raised eosinophil counts are being introduced to the market but there is some concern that these treatments will only work for patients with poor adherence to their asthma therapy. A recent RiRL study found that within the UK, a high proportion of patients at higher GINA steps appear to be adherent to therapy but remain uncontrolled in terms of exacerbations and symptoms. Therefore, there is a need to clarify whether there exists a population of patients with asthma who have persistent elevated blood eosinophil counts, persistent exacerbations and who are adherent to ICS.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsOPRI Pte Ltd
Department/Research groupResearch in Real Life Ltd
Organisation/affiliationOPRI Pte Ltd
Website/Homepagewww.rirl.org
Details of (Primary) lead investigator
Title Dr
Last name Khalikulov
First name Bakhtiyor
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/03/2015
Start date of data collection30/03/2015
Start date of data analysis
Date of interim report, if expected
Date of final study report30/12/201530/12/2015
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesTeva100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 12 Changi Business Park Avenue 1
Address line 2Level 2 
Address line 3486015 
CitySingapore 
Postcode 
CountrySingapore
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address david@opri.sg
Public Enquiries
Title Professor 
Last name Price 
First name Price 
Address line 12 Changi Business Park Avenue 1 
Address line 2Level 2 
Address line 3486015 
CitySingapore 
Postcode 
CountrySingapore 
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address david@opri.sg 
Top